University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Mitchel S. Berger, MD

Mitchel S. Berger, MD

Chair, Department of Neurological Surgery, and Director, Brain Tumor Research Center, UCSF
Berthold and Belle N. Guggenhime Professorship, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

Dr. Berger's main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery.

Dr. Berger is Director of the Neuro-Oncology Surgery Program. His current research interests involve identifying molecular markers in gliomas as correlates of tumor progression and prognosis. He also works in conjunction with Dr. Krys Bankiewicz to test small molecule inhibitors in brain tumors using convection enhanced delivery. Other collaborations include functional mapping localization of language pathways in the brain in conjunction with Dr. Robert Knight and the Cognitive Neuroscience Graduate Program at UC Berkeley. Dr. Berger is currently the Principal Investigator of UCSF's SPORE Brain Tumor Program. He is also the Principal Investigator of a Pediatric Brain Tumor Foundation Institute award to study the origins and treatment of pediatric brain tumors.

Education

Harvard University, Cambridge, MA, A.B., 1975, Social Psychology
University of Miami, Miami, FL, M.D., 1979, Medicine
University of California, San Francisco, CA (UCSF), Dept. of Neurological Surgery, Brain Tumor Research Center (BTRC) Research Fellow 1983 - 1984 Neurosurgery
UCSF, BTRC, Neuro-Oncology Service, Clinical Fellow, 7/85 - 12/85, Neurosurgery
Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Neurosurgery Fellow, 1/86 - 6/86, Neurosurgery


Professional Experience

  • 1980 - 1982
    Residency, Dept. of Neurological Surgery, University of California, San Francisco, CA (UCSF)
  • 1986 - 1992
    Asst. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1990 - 1992
    Assoc. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1995 - 1992
    American Cancer Society Prof. of Clinical Oncology, University of Washington, Seattle, WA
  • 1996 - 1992
    Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1997 - present
    Professor and Chair, Dept. of Neurological Surgery, UCSF, San Francisco, CA
  • 1997 - present
    Director, Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF

Honors & Awards

  • 1997-Present
    Joint Section on Tumors Advisory Council, American Association of Neurological Surgeons and Congress of Neurological Surgeons
  • 1997-1999
    Vice-President, Congress of Neurological Surgeons; President, Society for Neuro-Oncology
  • 2002-Present
    America’s Top Doctors, peer-nominated referral index from Castle Connolly
  • 2006
    Tumor Section, 2006 Ronald L. Bittner Lecturer; 2006 Farber Award Winner
  • 2007–Present
    Board of Directors of the American Association of Neurological Surgeons
  • 2007–Present
    Member of the American Board of Neurological Surgeons
  • 2010
    Vice-President, American Association of Neurological Surgeons
  • 2011
    President Elect, American Association of Neurological Surgeons
  • 2012
    President, American Association of Neurological Surgeons

Selected Publications

  1. Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020 Mar 13.
    View on PubMed
  2. Magill ST, Rubio RR, Berger MS. Principles of Supplemental Motor Area and Cingulate Tumor Resection With Asleep Trimodal Motor Mapping: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown). 2020 Mar 13.
    View on PubMed
  3. Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, Kline CN, Banerjee A, Reddy A, Oberheim Bush NA, Chang S, Braunstein S, Chang EF, Raffel C, Gupta N, Sun PP, Kim JYH, Moes G, Alva E, Li R, Bruggers CS, Alashari M, Wetmore C, Garg S, Dishop M, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Berger MS, Costello JF, Perry A, Solomon DA. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. Acta Neuropathol. 2020 Mar 10.
    View on PubMed
  4. Mischkulnig M, Kiesel B, Borkovec M, Wadiura LI, Benner D, Hosmann A, Hervey-Jumper S, Knosp E, Roessler K, Berger MS, Widhalm G. High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas. Lasers Surg Med. 2020 Mar 08.
    View on PubMed
  5. Yue JK, Phelps RRL, Chandra A, Winkler EA, Manley GT, Berger MS. Sideline Concussion Assessment: The Current State of the Art. Neurosurgery. 2020 Mar 03.
    View on PubMed
  6. Chandra A, Brandel MG, Wadhwa H, Almeida ND, Yue JK, Nuru MO, Cheng J, Lu S, Patel A, Essayed W, McDermott MW, Berger MS, Aghi MK. The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017. World Neurosurg. 2020 Feb 18.
    View on PubMed
  7. Wadiura LI, Mischkulnig M, Hosmann A, Borkovec M, Kiesel B, Rötzer T, Mercea PA, Furtner J, Hervey-Jumper S, Rössler K, Berger MS, Widhalm G. "Influence of corticosteroids and antiepileptic drugs on visible 5-ALA fluorescence in a series of initially suspected low-grade gliomas including WHO grade II, III and IV gliomas". World Neurosurg. 2020 Feb 08.
    View on PubMed
  8. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020 Feb 06.
    View on PubMed
  9. Golby AJ, Leuthardt EC, Duffau H, Berger MS. Introduction. Advances and future directions in brain mapping in neurosurgery. Neurosurg Focus. 2020 Feb 01; 48(2):E1.
    View on PubMed
  10. Lau CY, Seymann G, Imershein S, Amin A, Afsarmanesh N, Uppington J, Aledia A, Pretanvil S, Wilson B, Wong J, Varma J, Boggan J, Hsu FPK, Carter B, Berger M, Harrison JD. UC Care Check-A Postoperative Neurosurgery Operating Room Checklist: An Interrupted Time Series Study. J Healthc Qual. 2020 Jan 21.
    View on PubMed
  11. Lin CA, Berger MS. Advancing neuro-oncology of glial tumors from big data and multidisciplinary studies. J Neurooncol. 2020 Jan; 146(1):1-7.
    View on PubMed
  12. Mack C, Sendor RR, Solomon G, Ellenbogen RG, Myers E, Berger M, Sills A. Enhancing Concussion Management in the National Football League: Evolution and Initial Results of the Unaffiliated Neurotrauma Consultants Program, 2012-2017. Neurosurgery. 2019 Dec 03.
    View on PubMed
  13. Dalle Ore CL, Chandra A, Rick J, Lau D, Shahin M, Nguyen AT, McDermott M, Berger MS, Aghi MK. Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. Neurosurgery. 2019 12 01; 85(6):793-800.
    View on PubMed
  14. Oberheim Bush NA, Hervey-Jumper SL, Berger MS. Management of Glioblastoma, Present and Future. World Neurosurg. 2019 Nov; 131:328-338.
    View on PubMed
  15. Wadhwa H, Shah SS, Shan J, Cheng J, Beniwal AS, Chen JS, Gill SA, Mummaneni N, McDermott MW, Berger MS, Aghi MK. The neurosurgery applicant's "arms race": analysis of medical student publication in the Neurosurgery Residency Match. J Neurosurg. 2019 Nov 01; 1-9.
    View on PubMed
  16. Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol. 2019 Oct 14.
    View on PubMed
  17. Sankaran S, Andrews JP, Chicas M, Wachter RM, Berger MS. Patient safety movement in neurological surgery: the current state and future directions. J Neurosurg. 2019 Oct 04; 1-11.
    View on PubMed
  18. Young JS, Morshed RA, Mansoori Z, Cha S, Berger MS. Disruption of Frontal Aslant Tract Is Not Associated with Long-Term Postoperative Language Deficits. World Neurosurg. 2020 Jan; 133:192-195.
    View on PubMed
  19. Zhu P, Du XL, Blanco AI, Ballester LY, Tandon N, Berger MS, Zhu JJ, Esquenazi Y. Impact of facility type and volume in low-grade glioma outcomes. J Neurosurg. 2019 Sep 27; 1-11.
    View on PubMed
  20. Samuel N, Berger M. Cultural evolution: a Darwinian perspective on patient safety in neurosurgery. J Neurosurg. 2019 Sep 13; 1-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI